KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBITDA Margin: 2018-2025

Historic EBITDA Margin for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Sep 2025 value amounting to 43.16%.

  • Aurinia Pharmaceuticals' EBITDA Margin rose 2128.00% to 43.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.15%, marking a year-over-year increase of 3913.00%. This contributed to the annual value of 2.48% for FY2024, which is 4675.00% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported EBITDA Margin of 43.16% as of Q3 2025, which was up 40.97% from 30.62% recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' EBITDA Margin registered a high of 43.16% during Q3 2025, and its lowest value of -5,511.27% during Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' EBITDA Margin averaged around -6.64%, with its median value being 1.25% (2024).
  • Within the past 5 years, the most significant YoY rise in Aurinia Pharmaceuticals' EBITDA Margin was 14,493,321bps (2021), while the steepest drop was 12,648bps (2021).
  • Over the past 5 years, Aurinia Pharmaceuticals' EBITDA Margin (Quarterly) stood at -142.63% in 2021, then soared by 5,267bps to -89.96% in 2022, then spiked by 3,084bps to -59.12% in 2023, then spiked by 6,106bps to 1.95% in 2024, then soared by 2,128bps to 43.16% in 2025.
  • Its last three reported values are 43.16% in Q3 2025, 30.62% for Q2 2025, and 37.09% during Q1 2025.